Polaryx Therapeutics (PLYX) EPS (Basic) (2025 - 2026)
Polaryx Therapeutics' (PLYX) quarterly EPS (Basic) came in at -$0.03 in Q2 2026, down 26.67% year-over-year from -$0.04 in Q2 2025, and up 46.94% quarter-over-quarter from -$0.05 in Q1 2026.
Powered by 
Analysis
Polaryx Therapeutics (PLYX) EPS (Basic) (2025 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported EPS (Basic) for 2 consecutive years, with -$0.03 the latest figure, recorded in Q2 2026.
- On a quarterly basis, EPS (Basic) fell 26.67% year-over-year to -$0.03 in Q2 2026; TTM through Jun 2026 was -$0.21, a N/A change from a year earlier, with the FY2025 full-year figure at -$0.17, down 35.31% from the prior year.
- EPS (Basic) was -$0.03 for Q2 2026 at Polaryx Therapeutics, up from -$0.05 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$0.02 in Q2 2025 and troughed at -$0.11 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.01 Bn | 193.02 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 179.98 Bn | 176.80 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 82.02 Bn | 74.03 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 60.35 Bn | 55.16 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 53.69 Bn | 48.55 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 33.11 Bn | 29.80 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.21 Bn | 29.21 Bn | 1.16 Mn | -0.40 |
| 10 | Polaryx Therapeutics | 97.52 Mn | 85.98 Mn | - | -0.03 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.03 |
| Mar 31, 2026 | -0.05 |
| Jun 30, 2025 | -0.02 |
| Mar 31, 2025 | -0.11 |